Clinical Trial Results
The Safety of THIO Sequenced With Cemiplimab in NSCLC Remains Promising
Source – MAIA Biotechnology Two patients with advanced non-small cell lung cancer (NSCLC) have not experienced disease progression for 12.2 ...
Avutometinib/Defactinib Phase III Confirmatory Study in LGSOC Completes Design
Source – Verastem Oncology The FDA and Verastem Oncology have finalized the design of a Phase III clinical trial to ...
In unresectable/metastatic urothelial carcinoma, upfront nivolumab/chemotherapy prolongs survival
Source –Bristol-Myers Squibb Nivolumab plus chemotherapy showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival ...
IA Gemcitabine Provides Survival Benefit in Patients with Locally Advanced Pancreatic Cancer
Source – RenovoRx The interim results of the Phase III TIGeR-PaC study (NCT03257033) presented at the 2023 European Society of ...
Pirtobrutinib Shows Promise as a Novel CLL/SLL Treatment for Patients Previously Treated with BTK Inhibitors
Source – Eli Lilly On July 6, 2023, Eli Lilly and Company’s oncology unit announced that The New England Journal ...
Janssen rejoices at JNJ-2113A’s successful psoriasis study findings
Source – Johnson & Johnson On July 4, 2023, Janssen, a subsidiary of Johnson & Johnson announced positive initial results ...
DATOPOTAMAB DERUXTECAN MEETS DUAL PRIMARY ENDPOINT IN TROPION-LUNG01 PHASE III TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER
On July 3, 2023, AstraZeneca presented encouraging top-line results from the TROPION-Lung01 Phase III trial that demonstrated the positive efficacy ...
Fezolinetant’s Phase IIIb Trial Demonstrates Promising Topline Results in Treating Menopause-related Vasomotor Symptoms (VMS)
Source – Astellas Pharma Astellas Pharma recently announced positive preliminary findings on June 27, 2023, from the Phase IIIb DAYLIGHT ...
Novel BRG1/BRM Inhibitor in Metastatic Uveal Melanoma Shows Safety and Preliminary Efficacy
Source – Foghorn Therapeutics Foghorn Therapeutics has highlighted the safety and tolerability of FHD-286 in metastatic uveal melanoma (mUM) through ...
Clinical Activity Is Provoked by Teclistamab Triplet in R/R Multiple Myeloma
The Phase Ib (NCT04722146) MajesTEC-2 trial demonstrated promising clinical activity in patients with relapsed/refractory multiple myeloma (RRMM) when combining teclistamab ...
Missed trial procedures, made-up emails, and an unsuccessful endpoint make a mess Alzheimer’s agitation readout from BioXCel
Source – BioXcel Therapeutics On June 29, 2023, a potential breakthrough in the treatment of agitation episodes in Alzheimer’s disease ...
Imfinzi + Imjudo: Unprecedented 4-Year Survival in Advanced Liver Cancer
Source – AstraZeneca On 29 June 2023, new findings from the HIMALAYA Phase III trial revealed that AstraZeneca’s Imfinzi (durvalumab) ...
Combining mitazalimab with chemotherapy demonstrates significant antitumor activity in metastatic pancreatic ductal adenocarcinoma
Source – Alligator Bioscience On June 26, 2023 the combination of mitazalimab, a novel CD40 monoclonal antibody agonist, with chemotherapy ...
Epcoritamab Shows Promise in Follicular Lymphoma Trial
Source – Abbvie On 28 June 2023, AbbVie in collaboration with Genmab, disclosede the initial findings of the Phase I/II ...
Promising Objective Response Rate (ORR) Observed in Phase II Trial of Envafolimab for Sarcoma
Source: TRACON Pharmaceuticals Positive findings from the ongoing Phase II ENVASARC trial (NCT04480502) demonstrate that envafolimab (KN035), either as a ...
Lilly’s Retatrutide Shows Promising Phase II Results By Weight Reduction in Adults with Obesity and Overweight
Source – Eli Lilly On June 26, 2023, Eli Lilly and Company announced the release of new Phase II findings ...
Promising Phase IIb Results in Atopic Dermatitis: amlitelimab as a Groundbreaking Treatment
Source – Sanofi On June 27, 2023, Sanofi announced positive Phase IIb Results. Amlitelimab shows promise as a first-in-class investigational ...
Promising Early Antitumor Activity of Camrelizumab Plus Famitinib in Advanced Melanoma
A Phase II trial presented at the 2023 ASCO Annual Meeting showed that combining the PD-L1 inhibitor camrelizumab with the ...
Altuviiio a weekly Administration Provides Effective Bleed Prevention for Severe Hemophilia A in Children
Source – Sanofi On June 26, 2023, at the Annual Meeting of the International Society on Thrombosis and Haemostasis (ISTH) ...
Lilly’s SURMOUNT-2 Study Shows Tirzepatide Achieves Significant 15.7% Weight Reduction in Adults with Obesity and Type 2 Diabetes
Source – Eli Lilly On June 24, 2023, Eli Lilly and Company’s tirzepatide showed promising results in the SURMOUNT-2 Phase ...
Positive Phase IIIa Results: Once-Weekly Insulin Icodec Benefits Adults with Type 2 Diabetes
Source – Novo Nordisk Novo Nordisk, on June 25, 2023, released new findings from Phase IIIa trials, ONWARDS 1 and ...
Lilly’s Orforglipron Shows Promising Weight Reduction in Obesity and Overweight Patients: Phase II Findings
Source – Eli Lilly On June 23, 2023, Eli Lilly and Company announced the Phase II results for orforglipron, an ...
In patients with treatment-naive CLL, Venetoclax Plus Obinutuzumab Shows Durable Survival Benefits
According to 6-year results from the Phase III CLL14 trial (NCT02242942), fixed-duration venetoclax (Venclexta) plus obinutuzumab (Gazyva) therapy resulted in ...
uniQure craters on the gene therapy data from Huntington Disease
Source –uniQure On June 21, 2023 uniQure announced promising interim data, including up to 24 months of follow-up, from 26 ...
Merck’s Keytruda fails a study for early stomach cancer following metastatic disease victory
Source – Merck Inhibiting immune checkpoints hasn’t been very effective against stomach cancer. Merck has now added another failure to ...
Takeda Unveils Complete Phase III Trial Results for HYQVIA as Maintenance Therapy in CIDP at PNS Annual Meeting
Source: Takeda Takeda on June 20, 2023, released the complete findings from the pivotal Phase III ADVANCE-CIDP 1 clinical trial, ...
